Muckle-Wells Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Muckle-Wells Syndrome (MWS) is a rare autoinflammatory disorder clinically classified as one of the three forms of Cryopyrin-Associated Periodic Syndrome (CAPS). CAPS is a hereditary disorder that results from genetic mutations in the NOD-like receptor 3 (NLRP3) gene. These mutations lead to the overproduction of proinflammatory interleukin 1β (IL-1β), which is the underlying cause of CAPS symptoms. MWS is characterized by recurring episodes of fever, headache, urticarial rash, arthralgia, or arthritis that occur without a specific trigger. These episodes typically begin in early childhood, with a median age of onset at 0.8 years. 40% to 80% of individuals with MWS experience intense fatigue, which can lead to social isolation. In some patients, these episodes last more than 24 hours and can occur as frequently as 24 times per year. MWS patients at high risk for severe disease activity can be identified at the time of diagnosis. Female patients with hearing loss, musculoskeletal symptoms, elevated ESR, or low haemoglobin levels have a higher likelihood of severe MWS. Women with hearing loss. Differential diagnoses for MWS include Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), Juvenile Idiopathic Arthritis, Juvenile Systemic Granulomatosis, Hyperimmunoglobulinemia D with Periodic Fever Syndrome (HIDS), Familial Mediterranean Fever (FMF) and Behçet's disease. The hereditary recurrent fever disease mimics MWS the most is the syndrome associated with NALP 12 mutations, with cold-triggered urticarial during 5–10 days, abdominal pain, adenomegaly, headache, oral ulcers, and, in some patients, deafness.
·
The prevalence of Cryopyrin-Associated
Periodic Syndrome (CAPS) is estimated to be 1–10 cases per million in the USA.
Thelansis’s “Muckle-Wells Syndrome
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Muckle-Wells
Syndrome treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Muckle-Wells Syndrome across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Muckle-Wells Syndrome Market Forecast Patient-Based
Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with
sourcing, Market Event, and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment